Payment overview · 2025
General Payments
$317.15
16 reported records · 9 companies
Healthcare provider profile · identity verified
Ana Migone, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CARBONDALE, IL · NPI 1790753341
Verified facts
What the public records show
CMS Open Payments records show Ana Migone, M.D. received $317.15 in general payments during 2025 across 16 reported records.
Novo Nordisk Inc accounted for 33.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Shingrix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $107.41 | 33.9% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.53 | 14.0% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $35.76 | 11.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.72 | 9.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.85 | 7.2% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $22.72 | 7.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.44 | 7.1% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $19.26 | 6.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.46 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $317.15 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.18 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.18 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $44.53 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $44.53 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $35.76 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.01 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $30.78 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $28.72 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 47 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 21 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
21 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 369 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 364 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 309 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 268 | 71 |
| Lisinopril | Lisinopril | 267 | 77 |
| Gabapentin | Gabapentin | 261 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 74 |
| Losartan Potassium | Losartan Potassium | 229 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 69 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 219 | 36 |
| Furosemide | Furosemide | 200 | 55 |
| Ezetimibe | Ezetimibe | 187 | 54 |
| Metformin Hcl | Metformin Hcl | 164 | 46 |
| Jardiance | Empagliflozin | 155 | 37 |
| Omeprazole | Omeprazole | 150 | 43 |
| Allopurinol | Allopurinol | 146 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 53 |
| Eliquis | Apixaban | 125 | 26 |
| Buspirone Hcl | Buspirone Hcl | 122 | 24 |
| Potassium Chloride | Potassium Chloride | 117 | 39 |
| Pregabalin | Pregabalin | 117 | 20 |
| Tramadol Hcl | Tramadol Hcl | 117 | 25 |
| Alprazolam | Alprazolam | 113 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 32 |
| Lorazepam | Lorazepam | 108 | 23 |
| Montelukast Sodium | Montelukast Sodium | 101 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 26 |
| Spironolactone | Spironolactone | 94 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 19 |
| Famotidine | Famotidine | 85 | 29 |
| Raloxifene Hcl | Raloxifene Hcl | 78 | 18 |
| Tradjenta | Linagliptin | 77 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 76 | 22 |
| Carvedilol | Carvedilol | 73 | 21 |
| Celecoxib | Celecoxib | 70 | 19 |
| Nifedipine Er | Nifedipine | 70 | 23 |
| Lovastatin | Lovastatin | 69 | 17 |
| Metformin Hcl Er | Metformin Hcl | 66 | 18 |
| Sertraline Hcl | Sertraline Hcl | 63 | 15 |
| Donepezil Hcl | Donepezil Hcl | 62 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 37 |
| Simvastatin | Simvastatin | 56 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 20 |
| Febuxostat | Febuxostat | 48 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 12 |
| Rybelsus | Semaglutide | 47 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 12 |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Modafinil | Modafinil | 46 | suppressed |
| Sucralfate | Sucralfate | 45 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 11 |
| Januvia | Sitagliptin Phosphate | 44 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 14 |
| Azelastine Hcl | Azelastine Hcl | 43 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 39 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 11 |
| Ozempic | Semaglutide | 39 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 37 | 11 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 33 |
| Vilazodone Hcl | Vilazodone Hcl | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Meloxicam | Meloxicam | 35 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | 11 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 24 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Calcitriol | Calcitriol | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Nateglinide | Nateglinide | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 29 | suppressed |
| Linzess | Linaclotide | 29 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 14 |
| Diazepam | Diazepam | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 20 | 19 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Prednisone | Prednisone | 20 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Dexilant | Dexlansoprazole | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Oxycontin | Oxycodone Hcl | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 13 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nystatin | Nystatin | 14 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 13 |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Novolog | Insulin Aspart | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Terconazole | Terconazole | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $317.15 · 16 records | Novo Nordisk Inc | AREXVY, BEXSERO, Cologuard Collection Kit, DAYBUE, Dexcom G6 Transmitter, KISUNLA, Ozempic, PENMENVY, Rybelsus, SHINGRIX, VRAYLAR, WATCHMAN Access System, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error